EA201301040A1 - Гетероциклическое соединение и его применение - Google Patents

Гетероциклическое соединение и его применение

Info

Publication number
EA201301040A1
EA201301040A1 EA201301040A EA201301040A EA201301040A1 EA 201301040 A1 EA201301040 A1 EA 201301040A1 EA 201301040 A EA201301040 A EA 201301040A EA 201301040 A EA201301040 A EA 201301040A EA 201301040 A1 EA201301040 A1 EA 201301040A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
heterocyclic compound
hypertension
prodrugs
formulas
Prior art date
Application number
EA201301040A
Other languages
English (en)
Inventor
Таканобу Куроита
Ясухиро Имаеда
Коуити Иванага
Наохиро Тайа
Хидеказу Токухара
Йосиюки Фукасе
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41282529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201301040(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA201301040A1 publication Critical patent/EA201301040A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Соединения, представленные формулами (I), (II):где каждый символ такой, как определено в описании, и их пролекарства обладают превосходной ренин ингибирующей активностью и полезны в качестве средств для профилактики или лечения гипертонии, поражений различных органов, связанных с гипертонией, и т.п.
EA201301040A 2008-06-19 2009-06-17 Гетероциклическое соединение и его применение EA201301040A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008161049 2008-06-19
JP2009004882 2009-01-13

Publications (1)

Publication Number Publication Date
EA201301040A1 true EA201301040A1 (ru) 2014-01-30

Family

ID=41282529

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201301040A EA201301040A1 (ru) 2008-06-19 2009-06-17 Гетероциклическое соединение и его применение
EA201170051A EA019755B1 (ru) 2008-06-19 2009-06-17 Гетероциклическое соединение и его применение

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201170051A EA019755B1 (ru) 2008-06-19 2009-06-17 Гетероциклическое соединение и его применение

Country Status (38)

Country Link
US (5) US8466282B2 (ru)
EP (1) EP2297114B1 (ru)
JP (3) JP4800445B2 (ru)
KR (2) KR101207830B1 (ru)
CN (2) CN103373985B (ru)
AR (1) AR072166A1 (ru)
AU (1) AU2009261153B2 (ru)
BR (1) BRPI0914802B8 (ru)
CA (1) CA2728476C (ru)
CL (1) CL2010001361A1 (ru)
CO (1) CO6300862A2 (ru)
CR (2) CR20110001A (ru)
CY (1) CY1120995T1 (ru)
DK (1) DK2297114T3 (ru)
DO (2) DOP2010000381A (ru)
EA (2) EA201301040A1 (ru)
EC (1) ECSP11010770A (ru)
ES (1) ES2676289T3 (ru)
GE (2) GEP20135957B (ru)
HR (1) HRP20181370T1 (ru)
HU (1) HUE039416T2 (ru)
IL (1) IL209282A (ru)
JO (1) JO3465B1 (ru)
LT (1) LT2297114T (ru)
MA (1) MA32483B1 (ru)
MX (2) MX2010013602A (ru)
MY (1) MY160771A (ru)
NZ (2) NZ600238A (ru)
PE (2) PE20110067A1 (ru)
PL (1) PL2297114T3 (ru)
PT (1) PT2297114T (ru)
RS (1) RS57591B1 (ru)
SG (1) SG188117A1 (ru)
SI (1) SI2297114T1 (ru)
TW (2) TWI378096B (ru)
UY (1) UY31907A (ru)
WO (1) WO2009154300A2 (ru)
ZA (1) ZA201009073B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2202228B1 (en) 2007-10-15 2014-12-10 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
US8389511B2 (en) 2007-12-19 2013-03-05 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic heterocyclic derivative
GEP20135957B (en) * 2008-06-19 2013-11-11 Takeda Pharmaceuticals Co Heterocyclic compound and usage thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8658639B2 (en) 2009-06-24 2014-02-25 Dainippon Sumitomo Pharma Co., Ltd N-substituted-cyclic amino derivative
WO2011079105A1 (en) * 2009-12-23 2011-06-30 Abbott Laboratories Novel thienopyrrole compounds
TWI511967B (zh) * 2010-06-16 2015-12-11 Takeda Pharmaceutical 醯胺化合物之結晶
CA2815741A1 (en) * 2010-11-09 2012-05-18 F. Hoffmann-La Roche Ag Triazole derivatives as ligands for gaba receptors
US8742097B2 (en) * 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
CN104781226A (zh) * 2012-02-14 2015-07-15 陶氏环球技术有限责任公司 非离子型表面活性剂组合物
WO2013122260A1 (en) 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Tablet
RU2014149123A (ru) * 2012-06-26 2016-08-20 Саниона Апс Фенилтриазольное производное и его применение для модуляции ГАМКА-рецепторного комплекса
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
CN106414396B (zh) * 2014-04-10 2019-11-08 武田药品工业株式会社 制备杂环化合物的方法
WO2015171516A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
KR20170023061A (ko) 2014-06-18 2017-03-02 테티스 파마수티컬스 엘엘씨 활성제의 미네랄 아미노산 복합체
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
CA3026264A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
CN108727249A (zh) * 2018-07-07 2018-11-02 台州学院 3-二氟甲基哌啶盐酸盐及其衍生物的合成方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
RU2168510C2 (ru) 1991-07-31 2001-06-10 Такеда Кемикал Индастриз, Лтд. Гетероциклическое соединение, фармацевтическая композиция, способ антагонизирования ангиотензина ii
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
AP9600817A0 (en) 1995-06-06 1996-07-31 Pfizer Novel cryatal form of anhydrous 7-( [1A,5A,6A]-6-amino3-3-azabicyclo [3.1.0.] hex-3-yl) -6-fluro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acid, methanesulfonic acid salt.
UA58494C2 (ru) 1995-06-07 2003-08-15 Зенека Лімітед Производные n-гетероарилпиридинсульфонамида, фармацевтическая композиция, способ получения и способ противодействия влияниям эндотелина
BR9606619A (pt) 1995-09-01 1997-12-23 Lilly Co Eli Antagonistas do receptor de neuropeptídeo y indolil
TWI227240B (en) 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
WO2002100833A1 (fr) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Inhibiteurs de rho kinase
US20030078278A1 (en) 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
AU2002363250A1 (en) 2001-11-01 2003-05-12 Icagen, Inc. Pyrazole-amides and-sulfonamides
WO2003055482A1 (en) 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
JP4399269B2 (ja) 2002-03-08 2010-01-13 メルク エンド カムパニー インコーポレーテッド 有糸分裂性キネシン阻害薬
CA2500848A1 (en) 2002-10-18 2004-05-06 Merck & Co., Inc. Mitotic kinesin inhibitors
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
WO2004111033A1 (en) 2003-06-18 2004-12-23 Astrazeneca Ab 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
US7666862B2 (en) 2003-08-15 2010-02-23 Merck & Co., Inc. Mitotic Kinesin Inhibitors
CA2534065A1 (en) 2003-08-15 2005-03-03 Paul J. Coleman Dihydropyrrole derivatives as mitotic kinesin inhibitors
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
JP4795965B2 (ja) 2003-11-12 2011-10-19 エルジー・ライフ・サイエンシーズ・リミテッド メラノコルチン受容体のアゴニスト
TW200613274A (en) 2004-07-09 2006-05-01 Speedel Experimenta Ag Organic compounds
CA2575561A1 (en) 2004-08-10 2006-02-23 Incyte Corporation Amido compounds and their use as pharmaceuticals
CN101072561B (zh) 2004-10-07 2011-05-11 生命医药公司 二氨基烷烃天冬氨酸蛋白酶抑制剂
CA2587853A1 (en) * 2004-11-23 2006-06-01 Wyeth Gonadotropin releasing hormone receptor antagonists
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
AU2006227787A1 (en) 2005-03-16 2006-09-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
GB0511063D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
WO2007026664A1 (ja) 2005-08-30 2007-03-08 Asahi Kasei Pharma Corporation スルホンアミド化合物
FI20055498A0 (fi) 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
US8129411B2 (en) 2005-12-30 2012-03-06 Novartis Ag Organic compounds
TW200804359A (en) 2006-01-19 2008-01-16 Speedel Experimenta Ag Substituted 4-phenylpiperidines
US20100121048A1 (en) 2006-02-16 2010-05-13 Takanobu Kuroita Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension
US7790884B2 (en) * 2006-03-24 2010-09-07 Astellas Pharma Inc. Acylaminopiperidine compound
GB0607954D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US20090318430A1 (en) 2006-07-21 2009-12-24 Astex Therapeutics Limited Medical use of cyclin dependent kinases inhibitors
WO2008016666A2 (en) * 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
WO2008093737A1 (ja) 2007-01-31 2008-08-07 Dainippon Sumitomo Pharma Co., Ltd. アミド誘導体
JP4837701B2 (ja) 2007-04-20 2011-12-14 田辺三菱製薬株式会社 医薬組成物
US20090156612A1 (en) 2007-04-27 2009-06-18 Takanobu Kuroita Substituted imidazole compound and use thereof
JP2010163361A (ja) * 2007-04-27 2010-07-29 Dainippon Sumitomo Pharma Co Ltd キノリン誘導体
JP2010189275A (ja) 2007-06-14 2010-09-02 Dainippon Sumitomo Pharma Co Ltd ナフタレン誘導体
TWI452044B (zh) 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp 嗎啉衍生物
WO2009001915A1 (ja) 2007-06-28 2008-12-31 Takeda Pharmaceutical Company Limited 置換イミダゾール化合物およびその用途
JP2010208947A (ja) 2007-06-29 2010-09-24 Dainippon Sumitomo Pharma Co Ltd キノロン誘導体
JP2010229034A (ja) 2007-07-26 2010-10-14 Dainippon Sumitomo Pharma Co Ltd 二環性ピロール誘導体
EP2202228B1 (en) 2007-10-15 2014-12-10 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
JP2011037712A (ja) 2007-12-08 2011-02-24 Dainippon Sumitomo Pharma Co Ltd ４−アリールフェニル誘導体
US8389511B2 (en) 2007-12-19 2013-03-05 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic heterocyclic derivative
AR070454A1 (es) 2008-02-27 2010-04-07 Nycomed Gmbh Pirrolopirimidincarboxamidas y composiciones farmaceuticas que las comprenden
CA2717529A1 (en) 2008-03-11 2009-09-17 Cellzome Limited Sulfonamides as zap-70 inhibitors
JP2009298713A (ja) * 2008-06-11 2009-12-24 Daiichi Sankyo Co Ltd イミダゾチアゾール誘導体
GEP20135957B (en) * 2008-06-19 2013-11-11 Takeda Pharmaceuticals Co Heterocyclic compound and usage thereof
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬

Also Published As

Publication number Publication date
ECSP11010770A (es) 2011-02-28
BRPI0914802A2 (pt) 2015-08-11
US9045436B2 (en) 2015-06-02
JP5918746B2 (ja) 2016-05-18
CN103373985A (zh) 2013-10-30
DOP2010000381A (es) 2010-12-31
SI2297114T1 (sl) 2018-10-30
MX338557B (es) 2016-04-21
KR20110019428A (ko) 2011-02-25
CA2728476C (en) 2017-03-21
TWI378096B (en) 2012-12-01
MX2010013602A (es) 2011-03-15
ZA201009073B (en) 2012-03-28
US20100137587A1 (en) 2010-06-03
CN102123990A (zh) 2011-07-13
US20110178057A1 (en) 2011-07-21
US20150191486A1 (en) 2015-07-09
CR20130360A (es) 2013-09-03
US9221836B2 (en) 2015-12-29
KR101578264B1 (ko) 2015-12-16
HRP20181370T1 (hr) 2018-10-19
DK2297114T3 (en) 2018-07-09
JP5592831B2 (ja) 2014-09-17
CR20110001A (es) 2013-03-15
TWI472523B (zh) 2015-02-11
EA201170051A1 (ru) 2011-08-30
AR072166A1 (es) 2010-08-11
AU2009261153B2 (en) 2014-05-22
SG188117A1 (en) 2013-03-28
CN103373985B (zh) 2015-10-28
JP4800445B2 (ja) 2011-10-26
TW201002685A (en) 2010-01-16
JP2011157391A (ja) 2011-08-18
JP2014094950A (ja) 2014-05-22
TW201240987A (en) 2012-10-16
PE20110067A1 (es) 2011-02-18
WO2009154300A3 (en) 2010-06-03
ES2676289T3 (es) 2018-07-18
IL209282A0 (en) 2011-01-31
PT2297114T (pt) 2018-07-26
JO3465B1 (ar) 2020-07-05
EA019755B1 (ru) 2014-06-30
WO2009154300A2 (en) 2009-12-23
CO6300862A2 (es) 2011-07-21
KR101207830B1 (ko) 2012-12-04
RS57591B1 (sr) 2018-11-30
UY31907A (es) 2010-01-29
BRPI0914802B1 (pt) 2020-10-27
US8664380B2 (en) 2014-03-04
BRPI0914802B8 (pt) 2021-05-25
CA2728476A1 (en) 2009-12-23
PL2297114T3 (pl) 2018-10-31
NZ589825A (en) 2012-11-30
KR20120084778A (ko) 2012-07-30
US20120264733A1 (en) 2012-10-18
US20160046601A1 (en) 2016-02-18
CN102123990B (zh) 2014-07-09
CY1120995T1 (el) 2019-12-11
PE20140858A1 (es) 2014-08-04
GEP20135957B (en) 2013-11-11
EP2297114B1 (en) 2018-06-06
CL2010001361A1 (es) 2011-07-29
EP2297114A2 (en) 2011-03-23
HUE039416T2 (hu) 2018-12-28
MA32483B1 (fr) 2011-07-03
US8466282B2 (en) 2013-06-18
GEP20166443B (en) 2016-03-10
AU2009261153A1 (en) 2009-12-23
NZ600238A (en) 2014-04-30
MY160771A (en) 2017-03-15
DOP2013000123A (es) 2013-11-15
IL209282A (en) 2015-07-30
LT2297114T (lt) 2018-08-10
JP2011524853A (ja) 2011-09-08

Similar Documents

Publication Publication Date Title
EA201301040A1 (ru) Гетероциклическое соединение и его применение
EA201100447A1 (ru) Органические соединения
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
EA201200119A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
EA201000113A1 (ru) Пиразольные соединения
EA201101673A1 (ru) Замещенные хиназолины в качестве фунгицидов
EA201001455A1 (ru) Пиридины и пиразины в качестве ингибиторов pi3k (фосфатидилинозиткиназы-3)
EA201100125A1 (ru) Производные пирролопиридинилпиримидин-2-иламина
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA201100875A1 (ru) Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов
EA201070422A1 (ru) Производные оксадиазола
EA201390877A1 (ru) Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
EA201000950A1 (ru) Азолилметилоксираны, их применение, а также содержащие их средства
EA200800321A1 (ru) Ингибиторы гистондеацетилазы
EA201001124A1 (ru) Производные хинолина и их применение в качестве фунгицидов
EA201270378A1 (ru) Хиназолины в качестве ингибиторов калиевых каналов
EA201270254A1 (ru) Производные 5-фторпиримидинона
EA201000558A1 (ru) Производные имидазола
EA201070519A1 (ru) Соединения тропана
EA201000098A1 (ru) Производные хиназолинамида
EA200870514A1 (ru) Ацетиленовые гетероарильные соединения
EA201171211A1 (ru) Производные оксадиазола
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
EA201070442A1 (ru) НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ
EA201071229A1 (ru) Производные иминопиридина и их применение